125 related articles for article (PubMed ID: 15383199)
1. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers.
Reyderman L; Kosoglou T; Boutros T; Seiberling M; Statkevich P
Curr Med Res Opin; 2004 Sep; 20(9):1493-500. PubMed ID: 15383199
[TBL] [Abstract][Full Text] [Related]
2. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin.
Kosoglou T; Statkevich P; Meyer I; Cutler DL; Musiol B; Yang B; Zhu Y; Maxwell SE; Veltri EP
Curr Med Res Opin; 2004 Jun; 20(6):955-65. PubMed ID: 15200755
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
4. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
Reyderman L; Kosoglou T; Cutler DL; Maxwell S; Statkevich P
Curr Med Res Opin; 2005 Aug; 21(8):1171-9. PubMed ID: 16083526
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Gustavson LE; Schweitzer SM; Burt DA; Achari R; Rieser MJ; Edeki T; Chira T; Yannicelli HD; Kelly MT
Clin Ther; 2006 Mar; 28(3):373-87. PubMed ID: 16750452
[TBL] [Abstract][Full Text] [Related]
6. The interaction of diltiazem with lovastatin and pravastatin.
Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
[TBL] [Abstract][Full Text] [Related]
7. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
8. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
Reyderman L; Kosoglou T; Statkevich P; Pember L; Boutros T; Maxwell SE; Affrime M; Batra V
Int J Clin Pharmacol Ther; 2004 Sep; 42(9):512-8. PubMed ID: 15487810
[TBL] [Abstract][Full Text] [Related]
10. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
12. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
Jackson A; D'Avolio A; Watson V; Bonora S; Back D; Taylor J; Armenis K; Gazzard B; Moyle G; Boffito M
J Antimicrob Chemother; 2011 Apr; 66(4):885-9. PubMed ID: 21393207
[TBL] [Abstract][Full Text] [Related]
14. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
[TBL] [Abstract][Full Text] [Related]
15. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
Vaverková H
Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
[TBL] [Abstract][Full Text] [Related]
16. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
Feldman T; Koren M; Insull W; McKenney J; Schrott H; Lewin A; Shah S; Sidisin M; Cho M; Kush D; Mitchel Y
Am J Cardiol; 2004 Jun; 93(12):1481-6. PubMed ID: 15194017
[TBL] [Abstract][Full Text] [Related]
17. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Rogers JD; Zhao J; Liu L; Amin RD; Gagliano KD; Porras AG; Blum RA; Wilson MF; Stepanavage M; Vega JM
Clin Pharmacol Ther; 1999 Oct; 66(4):358-66. PubMed ID: 10546919
[TBL] [Abstract][Full Text] [Related]
18. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
Pitsavos C; Skoumas I; Tousoulis D; Metalinos G; Masoura C; Chrysohoou C; Papadimitriou L; Giotsas N; Toutouza M; Antoniades C; Stefanadis C
Int J Cardiol; 2009 May; 134(2):280-1. PubMed ID: 18353459
[TBL] [Abstract][Full Text] [Related]
19. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
20. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
